Back Pain News and Research

Latest Back Pain News and Research

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY) Cymbalta® (duloxetine HCl) to a broader pain population that will be further defined by the FDA, if approved.

20 Aug 2010

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.

20 Aug 2010

Scientist explains way to determine right size for breast implants

"Miami likes glitz",explains Christopher Craft, M.D., which is why women here tend to get larger breast implants in comparison to the rest of the country. Craft attended Georgetown University, graduated from the University of Tennessee Medical School, and completed his plastic surgery training at the University of North Carolina at Chapel Hill. He's a trained general and plastic surgeon specializing in surgical procedures of the body, breasts and skin.

18 Aug 2010

Discovery can lead to new class of drugs for chronic pain treatment

Researchers have made a discovery that could lead to a brand new class of drugs to treat chronic pain caused by inflammatory conditions such as arthritis and back pain without numbing the whole body.

17 Aug 2010

Benvenue Medical commences treatment in U.S. with Blazer Vertebral Augmentation System

Benvenue Medical, Inc., a developer of minimally invasive solutions for spine repair, announced today that it has treated the first patient in the United States with the Blazer Vertebral Augmentation System - a new device for the treatment of vertebral compression fractures (VCFs). The case was performed by Francis Facchini, M.D., partner, VIR Chicago, at Adventist GlenOaks Hospital in Glendale Heights, Illinois.

13 Aug 2010

Tips to prevent back pain for frequent laptop users

The symptoms are familiar to any student who has ever spent a long night pounding out a paper on a laptop computer: an aching neck, throbbing head and tingling fingers.Because of the way the computers are designed, using a laptop almost inevitably leads to poor posture, said Kevin Carneiro, DO, a doctor in the Department of Physical Medicine and Rehabilitation at the University of North Carolina at Chapel Hill School of Medicine. Incorrect posture and computer overuse can cause debilitating physical problems, such as sore muscles or repetitive stress injuries. Typing can also cause carpal tunnel syndrome, an injury to the nerve that passes through the wrist.

12 Aug 2010

Today's Opinions and Editorials: Bringing down health care costs; More on the Medicare trustees report

Short of transforming the medical payment system, can we bring down health care costs by feasible fixes? Yes, by reducing the number of services that must be covered by every insurance policy and requiring higher copayments for patients using the highest cost providers (Robert Pozen, 8/10).

11 Aug 2010

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.

10 Aug 2010

Adversity-exposure may protect against psychiatric disturbances that occur with CBP: Study

A new study by researchers at the University at Buffalo and the University of California, Irvine, to be published in the September issue of the journal Pain, reveals that, for people with chronic back pain, having a little adversity in your life can be protective and beneficial.

6 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

DURECT second-quarter net loss decreases to $6.3 million

DURECT Corporation announced today financial results for the three months ended June 30, 2010. Total revenues were $7.3 million for the three months ended June 30, 2010 compared to $4.9 million for the three months ended June 30, 2009. Net loss for the three months ended June 30, 2010 was $6.3 million, compared to a net loss of $7.5 million for the same period in 2009.

5 Aug 2010

Painkiller combinations cost more but are less effective: Report

In a new article in the journal Australian Prescriber, there is a warning that combination painkillers cause more side effects and may not provide the relief promised. This comes from the National Prescribing Service (NPS), Australia's medicine review body.

1 Aug 2010

Ortho Kinematics: 23 patients enrolled in KineGraph VMA clinical study

Ortho Kinematics, a privately held spine diagnostics company focused on revolutionizing spine motion analysis, announced today that it has begun a multi-site clinical study of the KineGraph VMA™, and that the initial 23 patients have been enrolled. The study will help determine which types of patients are best evaluated with KineGraph VMA testing. The KineGraph VMA is designed to provide functional diagnostic information to spine surgeons to be used in conjunction with MRI and plain X-rays.

29 Jul 2010

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Dendreon Corporation announced today the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer. The manuscript is published in the July 29, 2010 issue of the journal.

29 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

YesDTC, BioElectronics receive Japanese regulatory review notification for ActiPatch and Allay products

YesDTC Holdings, Inc., a direct-to-consumer marketer and global distributor of consumer goods and products and BioElectronics Corp., manufacturers of innovative pain relieving medical devices, today announced the companies have received notification of the pending review by Japanese government medical device regulators for the ActiPatch™ and Allay™ Menstrual Relief products. This review will take place on Wednesday, July 28th.

27 Jul 2010

Diagnostic guidelines for arthritis-related back pain result in excessive tests, delay in pain relief: Research

Slavishly following long-held guidelines for diagnosing the cause of arthritis-related back pain is resulting in excessive tests, delays in pain relief and wasteful spending of as much as $10,000 per patient, new Johns Hopkins-led research suggests.

26 Jul 2010

IBS associated with structural changes in specific brain regions

A large academic study has demonstrated structural changes in specific brain regions in female patients with irritable bowel syndrome, a condition that causes pain and discomfort in the abdomen, along with diarrhea, constipation or both

23 Jul 2010

Anthem Blue Cross and Blue Shield launches initiative to educate consumers on how to best access ER alternatives

At a time when health care costs continue to rise and hospitals are advertising emergency room availability, it is becoming more important to educate consumers on how to best access ER alternatives and receive the same care with less out-of-pocket cost. If a primary care physician isn't available, retail health clinics, walk-in doctor offices and urgent care centers can take less time and cost about the same as a regular doctor visit.

22 Jul 2010

Abbott second-quarter global sales increase 17.8% to $8.8 billion

Abbott today announced financial results for the second quarter ended June 30, 2010.

21 Jul 2010

Back Pain News and Research

Latest Back Pain News and Research

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Scientist explains way to determine right size for breast implants

Discovery can lead to new class of drugs for chronic pain treatment

Benvenue Medical commences treatment in U.S. with Blazer Vertebral Augmentation System

Tips to prevent back pain for frequent laptop users

Today's Opinions and Editorials: Bringing down health care costs; More on the Medicare trustees report

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

Adversity-exposure may protect against psychiatric disturbances that occur with CBP: Study

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

DURECT second-quarter net loss decreases to $6.3 million

Painkiller combinations cost more but are less effective: Report

Ortho Kinematics: 23 patients enrolled in KineGraph VMA clinical study

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

YesDTC, BioElectronics receive Japanese regulatory review notification for ActiPatch and Allay products

Diagnostic guidelines for arthritis-related back pain result in excessive tests, delay in pain relief: Research

IBS associated with structural changes in specific brain regions

Anthem Blue Cross and Blue Shield launches initiative to educate consumers on how to best access ER alternatives

Abbott second-quarter global sales increase 17.8% to $8.8 billion

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Back Pain News and Research

Latest Back Pain News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in